144 related articles for article (PubMed ID: 25955581)
1. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
Chapman AM; McNaughton BR
ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
[TBL] [Abstract][Full Text] [Related]
3. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.
Qiu W; Wu J; Walsh EM; Zhang Y; Chen CY; Fujita J; Xiao ZX
Oncogene; 2008 Jul; 27(29):4034-43. PubMed ID: 18332869
[TBL] [Abstract][Full Text] [Related]
4. Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.
Chapman AM; McNaughton BR
ACS Chem Biol; 2014 Oct; 9(10):2223-8. PubMed ID: 25137482
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of human oncoprotein gankyrin in Zebrafish.
Kim SY; Hur W; Choi JE; Kim D; Wang JS; Yoon HY; Piao LS; Yoon SK
Exp Mol Med; 2009 Jan; 41(1):8-16. PubMed ID: 19287195
[TBL] [Abstract][Full Text] [Related]
6. Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome.
Nakamura Y; Nakano K; Umehara T; Kimura M; Hayashizaki Y; Tanaka A; Horikoshi M; Padmanabhan B; Yokoyama S
Structure; 2007 Feb; 15(2):179-89. PubMed ID: 17292836
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
Higashitsuji H; Liu Y; Mayer RJ; Fujita J
Cell Cycle; 2005 Oct; 4(10):1335-7. PubMed ID: 16177571
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.
Chattopadhyay A; O'Connor CJ; Zhang F; Galvagnion C; Galloway WR; Tan YS; Stokes JE; Rahman T; Verma C; Spring DR; Itzhaki LS
Sci Rep; 2016 Apr; 6():23732. PubMed ID: 27046077
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin, the 26 S proteasome, the cell cycle and cancer.
Mayer RJ; Fujita J
Biochem Soc Trans; 2006 Nov; 34(Pt 5):746-8. PubMed ID: 17052188
[TBL] [Abstract][Full Text] [Related]
11. Gankyrin: a new oncoprotein and regulator of pRb and p53.
Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
[TBL] [Abstract][Full Text] [Related]
12. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome.
Dawson S; Apcher S; Mee M; Higashitsuji H; Baker R; Uhle S; Dubiel W; Fujita J; Mayer RJ
J Biol Chem; 2002 Mar; 277(13):10893-902. PubMed ID: 11779854
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Krzywda S; Brzozowski AM; Higashitsuji H; Fujita J; Welchman R; Dawson S; Mayer RJ; Wilkinson AJ
J Biol Chem; 2004 Jan; 279(2):1541-5. PubMed ID: 14573599
[TBL] [Abstract][Full Text] [Related]
14. Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.
Nanaware PP; Ramteke MP; Somavarapu AK; Venkatraman P
Proteins; 2014 Jul; 82(7):1283-300. PubMed ID: 24338975
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin: an intriguing name for a novel regulator of p53 and RB.
Lozano G; Zambetti GP
Cancer Cell; 2005 Jul; 8(1):3-4. PubMed ID: 16023592
[TBL] [Abstract][Full Text] [Related]
16. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2.
Nitta RT; Smith CL; Kennedy BK
PLoS One; 2007 Sep; 2(9):e963. PubMed ID: 17896003
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase.
Chapman AM; Rogers BE; McNaughton BR
Biochemistry; 2014 Nov; 53(44):6857-9. PubMed ID: 25343477
[TBL] [Abstract][Full Text] [Related]
18. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity.
Higashitsuji H; Higashitsuji H; Liu Y; Masuda T; Fujita T; Abdel-Aziz HI; Kongkham S; Dawson S; John Mayer R; Itoh Y; Sakurai T; Itoh K; Fujita J
Biochem Biophys Res Commun; 2007 Nov; 363(3):879-84. PubMed ID: 17904523
[TBL] [Abstract][Full Text] [Related]
19. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen X; Zhang M; Liu LX
Oncol Rep; 2009 Jul; 22(1):73-80. PubMed ID: 19513507
[TBL] [Abstract][Full Text] [Related]
20. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity.
Nagao T; Higashitsuji H; Nonoguchi K; Sakurai T; Dawson S; Mayer RJ; Itoh K; Fujita J
J Biol Chem; 2003 Mar; 278(12):10668-74. PubMed ID: 12525503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
